Exchange: NASDAQ·Updated 07:30 PM EDT

TENK TenX Keane Acquisition

$0.8565
$0.0048
(0.57%)
Today
Closed $0.8398
$0.0167
(1.99%)
After Hours
Mkt Cap$77.64M
Vol71,049.00

About TENK

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
58

Bullish Sentiment

How do you feel about TENK?

Advertisement|Remove ads.